We provide you with 20 years of free, institutional-grade data for CRSP stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CRSP. Explore the full financial landscape of CRSP stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Kulkarni Samarth | Sale | -28,500 | $126.67 | $3,610,095 | 2021-08-06 |
| Kulkarni Samarth | Derivatives Exercise | 28,500 | 2021-08-06 |
The information provided in this report about CRSP stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
CRISPR Therapeutics AG(NASDAQ:CRSP) 
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technolo...
Website: http://www.crisprtx.com
Founded: 1987
Full Time Employees: 458 (Dec 2022)
Sector: Healthcare
Industry: Biotechnology
